Announcement
29 Jul 2020
In July 2020, the Norwegian authorities introduced an export ban on rivaroxaban, apixaban, immunoglobulins and palivizumab following the outbreak of COVID-19.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
29 Jul 2020
Revocation date:
28 Jan 2021
Updated: 29 Jul 2020
Export ban
On 29 July 2020, the Norwegian Medicines Agency introduced an export ban on rivaroxaban, apixaban, certain immunoglobulins and palivizumab. The export ban was introduced due to concerns of shortage...
Sign in to see more
Related State Acts
28 Jan 2021
Norway: Introduction of export notification on certain medicines following the outbreak of COVID-19
01 Oct 2020
Norway: Introduction of export notification on all types of immunoglobulins following the outbreak of COVID-19
21 Aug 2020
Norway: Introduction of export notification on certain immunoglobulins
15 Jun 2020
Norway: Introduction of export notification requirement on several pharmaceutical goods (COVID-19)
12 Mar 2020
Norway: Introduction of export notification requirement on certain medicaments following the COVID-19 outbreak
Threads
See all
This state act is not part of any Thread yet.